Angiogenesis in psoriatic skin and its modifications after administration of etanercept: Videocapillaroscopic, histological and immunohistochemical evaluation

International Journal of Immunopathology and Pharmacology

Volumn 22, Issue 2, 2009, Pages 371-377

  Campanati, A ^a   Goteri, G ^a   Simonetti, O ^a   Ganzetti, G ^a   Giuliodori, K ^a   Giuliano, A ^a   Sabato, S ^a   Stramazzotti, D ^a   Gulini, E ^a   Dusi, D ^a   De Blasio, S ^a   Fabris, G ^a   Offidani, A ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Anti TNF alpha; Etanercept; Intravital videocapillaroscopy; Microangiopathy; Psoriasis

Indexed keywords

ETANERCEPT; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; VASCULOTROPIN;

ADULT; ANGIOGENESIS; ARTICLE; BODY SURFACE; CAPILLAROSCOPY; CLINICAL ARTICLE; DISEASE ACTIVITY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROANGIOPATHY; MICROCIRCULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; PSORIASIS SEVERITY INDEX; SKIN BIOPSY; TREATMENT DURATION; TREATMENT RESPONSE; VIDEOENDOSCOPY;

EID: 67650507115     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200902200214     Document Type: Article

References (19)

1. Hern S, Mortimer PS. In vivo quantification of microvessels in clinically uninvolved psoriatic skin and in normal skin. Br J Dermatol 2007; 156:1224-9.
2. Hern S, Stanton AW, Mellor RH, Harland CC, Levick JR, Mortimer PS. In vivo quantification of the structural abnormalities in psoriatic microvessels before and after pulsed dye laser treatment. Br J Dermatol 2005; 152:505-511
3. Bhushan M, Moore T, Herrick AL, Griffiths CE. Nailfold video capillaroscopy in psoriasis. Br J Dermatol. 2000; 142:1171-1176
4. Bull RH, Bates DO, Mortimer PS. Intravital video-capillaroscopy for the study of the microcirculation in psoriasis. Br J Dermatol 1992; 126:436-445
5. Trevisan G, Magaton Rizzi G, Dal Canton M. Psoriatic microangiopathy modifications induced by PUVA and etretinate therapy. A nail-fold capillary microscopic study. Acta Derm Venereol Suppl (Stockh) 1989; 146:53-56
6. Simonetti O, Lucarini G, Goteri G, Zizzi A, Biagini G, Lo Muzio L, Offidani A. VEGF is likely a key factor in the link between inflammation and angiogenesis in psoriasis: results of an immunohistochemical study. Int J Immunopathol Pharmacol 2006; 19:751-760 (Pubitemid 46145039)
7. Parent D, Bernard BA, Desbas C, et al. Spreading of psoriatic plaques: alteration of epidermal differentiation precedes capillary leakiness and anomalies in vascular morphology. J Invest Dermatol 1990; 95:333-340 (Pubitemid 20261868)
8. Butt C, Lim S, Greenwood C, Rahman P. VEGF, FGF1, FGF2 and EGF gene polymorphisms and psoriatic arthritis. BMC Musculoskelet Disord 2007; 8:1-7. (Pubitemid 46169616)
9. Yalçin B, Tezel GG, Arda N, Erman M, Alli N. Vascular endothelial growth factor, vascular endothelial growth factor receptor-3 and cyclooxygenase-2 expression in psoriasis. Anal Quant Cytol Histol 2007; 29:358-364 (Pubitemid 350304993)
10. Banno T, Gazel A, Blumenberg M. Effects of tumor necrosis factor-alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling. J Biol Chem 2004; 279:32633-32642 (Pubitemid 39014721)
11. Weinberg JM. An overview of infliximab, etanercept, efalizumab, alefacept as biologic therapy for psoriasis. Clin Ther 2003; 25810:2487-2505 (Pubitemid 37373927)
12. Papp KA, Tyring S, Lahfa M, et al: Etanercept Psoriasis Study Group. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152:1304-1312 (Pubitemid 40933433)
13. Krueger GG, Langley RG, Finlay AY, Griffiths CE, Woolley JM, Lalla D, Jahreis A. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol 2005; 153:1192-1199 (Pubitemid 41779576)
14. Paleolog E. Target effector role of vascular endothelium in the inflammatory response: insights from the clinical trial of anti-TNF alpha antibody in rheumatoid arthritis. Mol Pathol 1997; 50:225-233 (Pubitemid 27475771)
15. Van de Kerkof PCM, van Rennes H. de Grood R. Metabolic changes at the margin of the spreading psoriatic lesion. Br J Dermatol 1983; 108:647-652
16. Braverman IM, Sibley J. The response of psoriatic epidermis and microvessel to treatment with topical steroids and oral methotrexate. J Invest Dermatol 1985; 85:584-586 (Pubitemid 16204238)
17. Elder JT, Fisher GJ, Lindquist PB, et al. Overexpression of transforming growth factor alpha in psoriatic epidermis. Science 1989; 243:811-814 (Pubitemid 19062639)
18. Nickoloff BJ, Mitra RS, Varani J, Dixit VM, Polverini PJ. Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol 1994; 144:820-8. (Pubitemid 24172070)
19. Creamer D, Allen MH, Sousa A, Poston R, Barker JN. Localization of endothelial proliferation and microvascular expansion in active plaque psoriasis. Br J Dermatol 1997; 136:859-865 (Pubitemid 27283516)